Synagis

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2016
0519982016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
OBJECTIVE Palivizumab (Synagis [Abbot Laboratories, Kent, United Kingdom]) is recommended for the prevention of severe lower… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2005
2005
To evaluate the safety and immunogenicity of palivizumab, 55 children who received palivizumab in the IMpact-RSV trial received 5… (More)
Is this relevant?
2004
2004
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory… (More)
Is this relevant?
2004
2004
OBJECTIVE Use of palivizumab prophylactic therapy reduces the occurrence of hospitalizations for serious respiratory syncytial… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2003
2003
Human metapneumovirus (hMPV) is a newly recognized pathogen that like its better-known relative, human respiratory syncytial… (More)
Is this relevant?
Review
2002
Review
2002
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by… (More)
Is this relevant?
2001
2001
Respiratory Syncytial Virus (RSV) can be devastating to premature infants and children with chronic lung disease. Palivizumab… (More)
Is this relevant?
2000
2000
OBJECTIVE We developed an enzyme-linked immunosorbent assay (ELISA) for the quantitation of respiratory syncytial virus (RSV) in… (More)
Is this relevant?
1999
1999
Biochemical and functional testing of a humanized monoclonal antibody directed against Respiratory Syncytial Virus (Synagis) has… (More)
Is this relevant?
1999
1999
Palivizumab is a new anti-RSV monoclonal antibody product indicated for the prevention of serious lower respiratory tract disease… (More)
Is this relevant?